Article
Oncology
Nicole T. Gordon, Jaime J. Alberty-Oller, Kezhen Fei, Giampaolo Greco, Emily J. Gallagher, Derek LeRoith, Sheldon M. Feldman, Bridgid Killilea, Susan K. Boolbol, Lydia Choi, Neil Friedman, Melissa Pilewskie, Elisa Port, Amy Tiersten, Nina A. Bickell
Summary: Black women with breast cancer have higher body mass index and insulin resistance scores compared to White women, but their ODX recurrence scores do not correspondingly increase. This suggests that insulin resistance may be associated with breast cancer recurrence scores, but its impact may differ for Black women.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Ran Song, Dong-Eun Lee, Eun-Gyeong Lee, Seeyoun Lee, Han-Sung Kang, Jai Hong Han, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Youngmee Kwon, Jaeyeon Woo, So-Youn Jung
Summary: This retrospective study identified clinicopathological factors that can predict the Oncotype DX (ODX) risk group in early breast cancer patients, providing alternative options to the costly and time-consuming ODX test. The factors predicting the ODX risk group differ according to age, and can help guide decision-making on adjuvant chemotherapy.
Article
Oncology
Caglar Unal, Tolga Ozmen, Cetin Ordu, Kezban Nur Pilanci, Ahmet Serkan Ilgun, Erhan Gokmen, Elvina Almuradova, Mustafa Ozdogan, Niluefer Guler, Cihan Uras, Halil Kara, Orhan Demircan, Selver Isik, Gul Alco, Pinar Saip, Esra Aydin, Tomris Duymaz, Filiz Celebi, Kanay Yararbas, Gursel Soybir, Vahit Ozmen
Summary: This study aimed to evaluate survival and its correlation with ODx-RS in pT1-2, N0-N1mic patients treated with adjuvant therapy. The findings suggest that the addition of chemotherapy to endocrine therapy improves disease-free survival in patients aged <= 45 years with ODx-RS scores of >= 18.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Katya Losk, Rachel A. Freedman, Alison Laws, Olga Kantor, Elizabeth A. Mittendorf, Zhenying Tan-Wasielewski, Lorenzo Trippa, Nancy U. Lin, Eric P. Winer, Tari A. King
Summary: This study examined RS testing patterns, RS distribution, and factors associated with chemotherapy use in patients with pN1 breast cancer. Most RS-tested patients had low genomic risk, and a low RS independently influenced chemotherapy omission. In patients who underwent RS testing, short-term outcomes were excellent.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Oncology
Hao-Kuen Lin, Thuy Can, Adriana Kahn, Cynthia A. Flannery, Jess Hoag, Alekhya Akkunuri, Helen Bailey, Rick Baehner, Lajos Pusztai, Mariya Rozenblit
Summary: By analyzing the relationship between HER2 mRNA levels and HER2 immunohistochemistry categories, it has been found that there are cancers with higher mRNA levels within IHC 0 and low categories. Most HER2-low patients are HER2-negative according to the results of the Oncotype DX test, indicating no benefit from current adjuvant chemotherapies.
Article
Oncology
Caitlin Taylor, Jane Meisel, Aimee J. Foreman, Christy Russell, Dipankar Bandyopadhyay, Xiaoyan Deng, Lisa Floyd, Amelia Zelnak, Harry Bear, Ruth O'Regan
Summary: This study evaluated the clinical and pathologic complete response rates among early-stage HR + breast cancer patients who had been randomized to neoadjuvant endocrine therapy or neoadjuvant chemotherapy. Results showed that patients with intermediate RS results did not have significant differences in pathologic outcomes based on treatment type, suggesting that women with RS 0-25 may be able to omit chemotherapy without compromising outcomes.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Luca Licata, Giulia Viale, Mario Giuliano, Giuseppe Curigliano, Mariana Chavez-MacGregor, Julia Foldi, Oluchi Oke, Joseph Collins, Lucia Del Mastro, Fabio Puglisi, Filippo Montemurro, Claudio Vernieri, Lorenzo Gerratana, Sara Giordano, Alessia Rognone, Lorenzo Sica, Oreste Davide Gentilini, Stefano Cascinu, Lajos Pusztai, Antonio Giordano, Carmen Criscitiello, Giampaolo Bianchini
Summary: This study evaluates whether Oncotype DX improves confidence and agreement among oncologists in adjuvant chemotherapy recommendations for ER+/HER2- early-stage breast cancers. The study found that using Oncotype DX significantly reduces discordance and uncertainty among oncologists, and improves agreement in adjuvant chemotherapy recommendations for patients.
Article
Oncology
Natalie F. Berger, Brittney S. Zimmerman, Serena Tharakan, Kelly Suchman, Krystal P. Cascetta, Julia Blanter, Erin Moshier, Meng Ru, Shabnam Jaffer, Amy Tiersten
Summary: The study evaluated treatment and outcomes of patients with early-stage HR+ BC with high-risk ODx RS, showing that select patients may choose to forgo chemotherapy in favor of more aggressive endocrine therapy and ovarian suppression. Chemotherapy treatment did not lead to significant benefit for patients with high-risk ODx RS.
Article
Oncology
Valeria Romeo, Renato Cuocolo, Luca Sanduzzi, Vincenzo Carpentiero, Martina Caruso, Beatrice Lama, Dimitri Garifalos, Arnaldo Stanzione, Simone Maurea, Arturo Brunetti
Summary: In this study, a machine learning model was developed to predict the Oncotype DX score using DCE-MRI images of breast cancer patients. The model achieved an accuracy of 60% in the training set and 63% (AUC = 0.66) in the test set. These findings support the use of radiomics and machine learning for prognostic data prediction in breast cancer, with potential clinical applications.
Article
Oncology
Rachel M. Layman, Heather Lin, Angelica M. Gutierrez Barrera, Meghan S. Karuturi, Clinton Yam, Banu K. Arun
Summary: BRCA-associated early-stage hormone receptor-positive breast cancers have distinctive features compared to those without mutations. However, BRCA status does not significantly impact relapse-free survival and overall survival.
Article
Oncology
Jing Wang, Hui Chen, Jenna Koenig, Yun Wu, Isabelle Bedrosian, Banu Arun, Qingqing Ding, Laila Khazai, Erika Resetkova, Lei Huo, Nour Sneige, Constance Albarracin
Summary: This study evaluated the concordance of Oncotype DX recurrence scores (RS) in multifocal tumors and analyzed the pathological predictors of discordance. The results showed that bilateral synchronous tumors had higher discordance in Oncotype RS, which may be associated with discordant histologic grade or Ki67.
BREAST CANCER RESEARCH AND TREATMENT
(2023)
Article
Cell Biology
Ayat Lashen, Michael S. Toss, Wakkas Fadhil, Georgette Oni, Srinivasan Madhusudan, Emad Rakha
Summary: This study aimed to compare the performance of Oncotype DX with conventional clinicopathological parameters in ER+/HER2- breast cancer. The results showed a significant correlation between Oncotype DX and tumor grade, type, ER and PR expression, and Ki67 index. Therefore, these tumor features can be used as surrogate markers in certain scenarios.
Article
Oncology
Michael Crager, Sameera R. Wijayawardana, Aaron M. Gruver, Andrea Blacklock, Christy Russell, Frederick L. Baehner, Francisco Sapunar
Summary: This study assessed the correlation between Oncotype Dx (R) assay and Ki-67 IHC MIB-1 assay. The results showed a moderately positive correlation, suggesting that they should not be used interchangeably in clinical practice.
BREAST CANCER RESEARCH
(2022)
Article
Oncology
Bradley M. M. Turner, Brian S. S. Finkelman, David G. G. Hicks, Numbere Numbereye, Ioana Moisini, Ajay Dhakal, Kristin Skinner, Mary Ann G. Sanders, Xi Wang, Michelle Shayne, Linda Schiffhauer, Hani Katerji, Huina Zhang
Summary: In the era of precision cancer medicine, the cost and accessibility of multigene assays pose challenges for risk-stratification of breast cancer patients. This study presents the Rochester Modified Magee algorithm as an alternative method for clinical risk-assessment and stratification, offering cost savings and accessibility for patients without access to multigene testing.
Article
Oncology
Michelle Zhang, Meredith Sadinski, Dana Haddad, Min Sun Bae, Danny Martinez, Elizabeth A. Morris, Peter Gibbs, Elizabeth J. Sutton
Summary: The study revealed an association between BPE metrics in the non-tumor breast and tumor Oncotype Dx recurrence score, suggesting a potential relationship between the breast microenvironment and likelihood of recurrence and response to chemotherapy.
FRONTIERS IN ONCOLOGY
(2021)